ASX:CYP Cynata Therapeutics (CYP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Cynata Therapeutics Stock (ASX:CYP) 30 days 90 days 365 days Advanced Chart Get Cynata Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume159,853 shsAverage VolumeN/AMarket CapitalizationA$57.60 millionP/E RatioN/ADividend Yield13.95%Price TargetN/AConsensus RatingN/A Company Overview Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, brain cancer, sepsis, acute respiratory distress syndrome, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia. Read More Receive CYP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cynata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CYP Stock News HeadlinesWill Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?August 30, 2025 | finance.yahoo.comCynata Therapeutics Ltd (CYP) - Investing.com UKAugust 23, 2025 | uk.investing.comThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he’s kneecapped the Federal Reserve… | Banyan Hill Publishing (Ad)Diabetic Foot Ulcers Market to Experience Notable Growth by 2034, DelveInsight Predicts | Topadur Pharma, Cynata Therapeutics, Transwell Biotech, Aposcience, Ilya Pharma ...August 22, 2025 | theglobeandmail.comCynata Therapeutics Issues Shares to Strengthen Financial PositionAugust 22, 2025 | msn.comCynata Therapeutics Announces Quotation of New SecuritiesAugust 22, 2025 | msn.comCynata Therapeutics to Present at Bioshares Biotech Summit, Highlighting Key DevelopmentsAugust 6, 2025 | tipranks.comCynata Therapeutics Hosts Investor Webinar to Discuss Progress and Future PlansAugust 4, 2025 | tipranks.comSee More Headlines CYP Stock Analysis - Frequently Asked Questions How were Cynata Therapeutics' earnings last quarter? Cynata Therapeutics Limited (ASX:CYP) announced its earnings results on Wednesday, February, 27th. The company reported ($0.03) EPS for the quarter, meeting analysts' consensus estimates of ($0.03). Cynata Therapeutics had a negative net margin of 420.82% and a negative trailing twelve-month return on equity of 100.01%. What other stocks do shareholders of Cynata Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cynata Therapeutics investors own include Allied Gaming & Entertainment (AGAE), Avino Silver & Gold Mines (ASM), Academy Sports and Outdoors (ASO), Bank of America (BAC), Berkeley Energia (BKY), Global X Cloud Computing ETF (CLOU) and Eaton Vance Tax-Advantaged Global Dividend Opportunities Fund (ETO). Company Calendar Last Earnings2/27/2019Today9/15/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:CYP CIKN/A Webwww.cynata.com Phone61 3 9824 5254FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$9.74 million Net Margins-420.82% Pretax MarginN/A Return on Equity-100.01% Return on Assets-46.70% Debt Debt-to-Equity RatioN/A Current Ratio5.58 Quick Ratio9.23 Sales & Book Value Annual SalesA$2.32 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow11.93 Book ValueA$0.04 per share Price / BookN/AMiscellaneous Outstanding Shares180,680,000Free FloatN/AMarket CapA$57.60 million OptionableNot Optionable Beta0.93 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (ASX:CYP) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored“Godfather of AI’s” dire warningAI pioneer Geoffrey Hinton warns the technology could create massive unemployment and widen inequality, but Po...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cynata Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Cynata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.